药品流通治理综述与评价

世界主要药品消费国都将药品作为特殊商品进行管制,药品流通渠道治理成为政府管理的重要工作。自1984年中国药品流通引入多元市场主体后,药品流通无序竞争,由此带来"药价虚高""医院大处方"等诸多问题。为此,国家和各地方政府积极探索药品流通治理模式。但在新医改明确提出基本医疗回归公益导向前,渠道治理基本陷于多元主体间的利益博弈和喋喋不休的政策争论中。文章通过对基本药物制度实施前后药品流通治理的综述和评价,发现机制缺陷与治理难题,并参考国外治理经验提出:政府应将治理重点放在监控医疗机构行为和药品科学定价上,同时积极引导药品流通规模化经营。

Professional Survey and Evaluation to Drug Circulation Governing

All main drug consuming countries in the world consider drugs as a special commodity to supervise, so governing the drug circulating channel is becoming an important job in government's management. Since multi-market subject had been drawn into the drug circulation in China in 1984, drug circulation started to compete disorderly, hence many issues, such as: virtual height in drug price, polypharmacy in hospital, appeared. Therefore, the State and each local government try to explore drug circulation control mode. However, before the orientation which basic medical treatment in new medical reform returns to public welfare was put forward to, measures for treatment almost were immersed in interest gaming among multi subjects in channel and babbling policy argument. By professional survey and evaluation to drug circulation governing before and after carrying out basic drug system in China, the paper found the difficulties and defects in drug circulation channel control. By taking the successful experiences as references in drug circulation control gained by those main drug consuming countries in the world, it suggests that the government should focus on rational medical behavior supervising and scientific drug pricing, active leading drug circulation to large-scale operation